Luca Issi
Stock Analyst at RBC Capital
(3.90)
# 655
Out of 5,111 analysts
214
Total ratings
49.25%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $68.45 | +16.87% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $16.11 | +67.60% | 6 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $7 → $10 | $12.92 | -22.60% | 3 | Dec 8, 2025 | |
| MRNA Moderna | Maintains: Sector Perform | $28 → $25 | $29.92 | -16.44% | 18 | Nov 21, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Sector Perform | $57 → $28 | $26.85 | +4.28% | 1 | Nov 20, 2025 | |
| KRRO Korro Bio | Downgrades: Sector Perform | $85 → $8 | $7.96 | +0.50% | 8 | Nov 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $42 → $50 | $56.25 | -11.11% | 15 | Nov 11, 2025 | |
| RGNX REGENXBIO | Maintains: Outperform | $17 → $19 | $13.83 | +37.38% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $14 → $9 | $9.14 | -1.53% | 7 | Nov 7, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $23 → $30 | $19.59 | +53.14% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $45 | $20.43 | +120.26% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $850 → $860 | $850.95 | +1.06% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $79.76 | +2.81% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $61 → $72 | $71.86 | +0.19% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $435 → $500 | $391.50 | +27.71% | 28 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $210 → $230 | $213.24 | +7.86% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.47 | +580.27% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $24.56 | -26.71% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $9.76 | +104.92% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.44 | +354.55% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $14.17 | +19.97% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.90 | +46.07% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $10.95 | +219.63% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $26.83 | -3.09% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $52.12 | +34.31% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $38.90 | +46.53% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.44 | +63.93% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $36.23 | +112.53% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.71 | +718.71% | 5 | Aug 7, 2024 |
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $68.45
Upside: +16.87%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $16.11
Upside: +67.60%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $12.92
Upside: -22.60%
Moderna
Nov 21, 2025
Maintains: Sector Perform
Price Target: $28 → $25
Current: $29.92
Upside: -16.44%
Agios Pharmaceuticals
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $26.85
Upside: +4.28%
Korro Bio
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $7.96
Upside: +0.50%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $56.25
Upside: -11.11%
REGENXBIO
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $13.83
Upside: +37.38%
Intellia Therapeutics
Nov 7, 2025
Maintains: Sector Perform
Price Target: $14 → $9
Current: $9.14
Upside: -1.53%
Dyne Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $19.59
Upside: +53.14%
Nov 4, 2025
Maintains: Outperform
Price Target: $65 → $45
Current: $20.43
Upside: +120.26%
Oct 31, 2025
Maintains: Outperform
Price Target: $850 → $860
Current: $850.95
Upside: +1.06%
Oct 30, 2025
Maintains: Outperform
Price Target: $80 → $82
Current: $79.76
Upside: +2.81%
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $61 → $72
Current: $71.86
Upside: +0.19%
Sep 19, 2025
Maintains: Outperform
Price Target: $435 → $500
Current: $391.50
Upside: +27.71%
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $213.24
Upside: +7.86%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.47
Upside: +580.27%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $24.56
Upside: -26.71%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $9.76
Upside: +104.92%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.44
Upside: +354.55%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $14.17
Upside: +19.97%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $8.90
Upside: +46.07%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $10.95
Upside: +219.63%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $26.83
Upside: -3.09%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $52.12
Upside: +34.31%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $38.90
Upside: +46.53%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.44
Upside: +63.93%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $36.23
Upside: +112.53%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.71
Upside: +718.71%